Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

 
• By Mandy Jackson

Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Rozlytrek will compete with Vitrakvi for NTRK gene fusion patients. • Source: Shutterstock

More from New Products

More from Scrip